
|Articles|May 17, 2019
When to consider corneal cross-linking treatment
Author(s)Julianne Mobilian
Audrey Talley Rostov, MD, discusses corneal cross-linking (CXL) complications, and when to consider CXL treatment
Advertisement
RELATED:
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Lotus submits NDA in South Korea for LENZ’s presbyopia treatment VIZZ
2
FDA approves Amneal Pharmaceuticals' cyclosporine ophthalmic emulsion 0.05%.
3
Collarettes common but largely stable in moderate-to-severe dry eye patients
4
EYDENZELT, Celltrion’s biosimilar referencing EYLEA, approved in Canada
5

















































.png)


